About DNA Nanobots
DNA Nanobots is a company based in Powell (United States) founded in 2021 by Melika Shahhosseini and Christopher Lucas. DNA Nanobots has raised $3.5 million across 2 funding rounds. DNA Nanobots offers products and services including DNA Nanoparticle Platform and Gene Therapy Delivery. DNA Nanobots operates in a competitive market with competitors including Curapath, Flashpoint Therapeutics, Vim Meditech, Magle Group and Biocydex, among others.
- Headquarter Powell, United States
- Founders Melika Shahhosseini, Christopher Lucas
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Dna Nanobots, Llc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$3.5 M (USD)
in 2 rounds
-
Latest Funding Round
$3.5 M (USD), Series A
Dec 17, 2025
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of DNA Nanobots
DNA Nanobots offers a comprehensive portfolio of products and services, including DNA Nanoparticle Platform and Gene Therapy Delivery.
Provides targeted delivery for drugs and genes using nanotechnology
Enables non-viral gene delivery to specific tissues for treatment
Funding Insights of DNA Nanobots
DNA Nanobots has successfully raised a total of $3.5M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $3.5 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by DNA Nanobots
Investment portfolio details for DNA Nanobots
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - DNA Nanobots
Detailed financials for DNA Nanobots
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Dna Nanobots Comparisons
Peer comparison for DNA Nanobots
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of DNA Nanobots
DNA Nanobots operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Curapath, Flashpoint Therapeutics, Vim Meditech, Magle Group and Biocydex, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of drug delivery systems for therapeutic purposes
|
|
| Locked | Locked | Locked |
Flashpoint Therapeutics is developing nanotherapeutic candidates that can deliver precise RNA, DNA, and peptide payloads to specific cells at the right time.
|
|
| Locked | Locked | Locked |
Specializes in developing and manufacturing innovative parenteral drug delivery systems and sterile injectables.
|
|
| Locked | Locked | Locked |
Develops medical technologies for pharmaceuticals, therapeutics, and biopolymers.
|
|
| Locked | Locked | Locked |
Preclinical drug discovery, formulation and drug delivery R&D services
|
Detailed competitors of DNA Nanobots
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Dna Nanobots
Complete news archive for DNA Nanobots
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DNA Nanobots
DNA Nanobots was founded in 2021 and raised its 1st funding round 3 years after it was founded.
DNA Nanobots is headquartered in Powell, United States. It is registered at Powell, Wyoming, United States.
DNA Nanobots is a funded company, having raised a total of $3.5M across 2 funding rounds to date.
DNA Nanobots was founded in 2021 in Powell, United States, as a biotech firm. Nanotechnology is applied to enable precise delivery of chemotherapy, vaccines, and gene therapy. A technology for efficient and dependable transport has been created. Operations center on building biopharma collaborations, supported by a recent pre-seed funding round. The focus remains on advancing therapeutic applications in the sector.
DNA Nanobots's top competitors include Flashpoint Therapeutics, Curapath and Biocydex.
DNA Nanobots offers DNA Nanoparticle Platform and Gene Therapy Delivery.